Table 4.
Private sector availability of anti-malarial drugs and malaria diagnostics, among anti-malarial-stocking outlets
| Private Sector Total N = 2596 (95% CI) |
Eastern (N = 785) (95% CI) |
Central (N = 350) (95% CI) |
Western (N = 823) (95% CI) |
Coastal N = (638) (95% CI) |
|
|---|---|---|---|---|---|
| Availability of anti-malarialsa | |||||
| Any ACTb | 41.7 (36.9, 46.6) | 65.6 (59.5, 71.2) | 36.7 (27.6, 46.8) | 14.1 (11.2, 17.5) | 19.0 (14.2, 25.0) |
| Chloroquine | 41.8 (38.4, 45.3) | 24 (20.1, 28.3) | 43.5 (37.0, 50.2) | 47.7 (41.6, 53.8) | 68.6 (62.4, 74.2) |
| Primaquine | 7.7 (4.9, 10.4) | 7.5 (5.4, 10.4) | 11.1 (6.4, 18.4) | 2.9 (1.6, 5.2) | 1.0 (0.5, 1.9) |
| Oral AMT | 27.7 (23.8, 31.7) | 25.0 (18.9, 32.4) | 31.4 (24.8, 38.9) | 54.1 (49.4, 58.7) | 15.4 (11.7, 20.2) |
| Non-oral AMT | 11 (8.6, 13.4) | 11.7 (7.7, 17.3) | 11.8 (8.6, 16.2) | 18.3 (15.0, 22.2) | 5.5 (3.3, 9.0) |
| N = 2890 | N = 904 | N = 398 | N = 877 | N = 711 | |
|---|---|---|---|---|---|
| Availability of blood testingc | |||||
| Any malaria blood testing | 15.4 (12.6, 18.1) | 21.0 (17.2, 25.4) | 14.8 (10.4, 20.5) | 8.4 (6.0, 11.7) | 8.7 (5.7, 13.0) |
| Malaria microscopy | 0.6 (0.2, 0.9) | 0.6 (0.3, 1.2) | 0.7 (0.2, 2.0) | 0.7 (0.3, 1.5) | 0.2 (0.0, 0.8) |
| RDTs | 14.9 (12.3, 17.6) | 20.5 (16.7, 24.8) | 14.2 (9.9, 19.8) | 8.2 (5.8, 11.4) | 8.7 (5.7, 13.0) |
AMT artemisinin monotherapy
aAnti-malarial-stocking outlets have at least one anti-malarial in stock on the day of the survey, verified by presence of at least one anti-malarial recorded in the anti-malarial audit sheet
bAt the time of the 2015/2016 Myanmar ACTwatch outlet survey, AL, DHA-PP, and ASMQ were the first-line treatments for uncomplicated falciparum malaria. There was no ASMQ audited during the 2015/2016 survey
cBlood testing availability is reported among outlets that either had anti-malarials in stock on the day of the survey or reportedly stocked anti-malarials in the previous 3 months